Fortis Capital Advisors LLC Invests $797,000 in Kenvue Inc. $KVUE

Key Points

• Fortis Capital Advisors LLC acquired 33,238 shares of Kenvue Inc. during the first quarter, totaling approximately $797,000.
• Kenvue recently declared a quarterly dividend of $0.2075 per share, marking an increase from the previous quarter's dividend.
• Analysts have mixed views on Kenvue, with ratings varying from a "strong sell" to "buy," resulting in a consensus rating of "Hold" and a price target of $24.21.

Fortis Capital Advisors LLC bought a new position in Kenvue Inc. (NYSE:KVUE - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 33,238 shares of the company's stock, valued at approximately $797,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Starboard Value LP bought a new position in shares of Kenvue in the fourth quarter valued at approximately $467,864,000. Vanguard Group Inc. boosted its holdings in shares of Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock valued at $5,494,882,000 after acquiring an additional 10,600,682 shares in the last quarter. Third Point LLC bought a new position in shares of Kenvue in the first quarter valued at approximately $213,422,000. Maverick Capital Ltd. bought a new position in shares of Kenvue in the first quarter valued at approximately $203,036,000. Finally, Nuveen LLC bought a new position in shares of Kenvue in the first quarter valued at approximately $187,123,000. Institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 0.9%

Shares of NYSE:KVUE traded up $0.18 during mid-day trading on Friday, hitting $19.03. The stock had a trading volume of 26,726,491 shares, compared to its average volume of 23,182,142. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The company has a market cap of $36.52 billion, a PE ratio of 25.71, a P/E/G ratio of 2.71 and a beta of 0.83. Kenvue Inc. has a 12-month low of $17.15 and a 12-month high of $25.17. The company's 50 day moving average is $21.14 and its 200-day moving average is $22.23.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.28 by $0.01. The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm's quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date was Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's payout ratio is currently 112.16%.

Wall Street Analyst Weigh In

KVUE has been the subject of several recent analyst reports. Canaccord Genuity Group decreased their price objective on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a report on Friday, August 8th. Royal Bank Of Canada decreased their price objective on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a report on Friday, August 8th. UBS Group decreased their price objective on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a report on Thursday, July 17th. Bank of America cut their target price on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Finally, Citigroup cut their target price on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Kenvue presently has an average rating of "Hold" and a consensus target price of $24.21.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.